JP2012521191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521191A5 JP2012521191A5 JP2011551173A JP2011551173A JP2012521191A5 JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5 JP 2011551173 A JP2011551173 A JP 2011551173A JP 2011551173 A JP2011551173 A JP 2011551173A JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence provided
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003042 antagnostic effect Effects 0.000 claims 12
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 7
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 7
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 6
- 102000050320 human TNFRSF4 Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 229920001427 mPEG Polymers 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920002859 polyalkenylene Polymers 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15303809P | 2009-02-17 | 2009-02-17 | |
| US61/153,038 | 2009-02-17 | ||
| PCT/US2010/024377 WO2010096418A2 (en) | 2009-02-17 | 2010-02-17 | Antibody molecules having specificity for human ox40 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015063849A Division JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトｏｘ４０に対する特異性を有する抗体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012521191A JP2012521191A (ja) | 2012-09-13 |
| JP2012521191A5 true JP2012521191A5 (enExample) | 2014-04-17 |
| JP5782385B2 JP5782385B2 (ja) | 2015-09-24 |
Family
ID=42634416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551173A Expired - Fee Related JP5782385B2 (ja) | 2009-02-17 | 2010-02-17 | ヒトｏｘ４０に対する特異性を有する抗体分子 |
| JP2015063849A Pending JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトｏｘ４０に対する特異性を有する抗体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015063849A Pending JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトｏｘ４０に対する特異性を有する抗体分子 |
Country Status (34)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010216152B2 (en) | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| LT2609118T (lt) * | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| KR102119840B1 (ko) * | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| JP6038920B2 (ja) * | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ｏｘ４０抗体およびそれを使用する方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| JP6411214B2 (ja) | 2011-11-11 | 2018-10-24 | ユーシービー バイオファルマ エスピーアールエル | アルブミン結合抗体及びその結合断片 |
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| WO2013086419A1 (en) * | 2011-12-09 | 2013-06-13 | California Institute Of Technology | Polymer scaffolds and their use in the treatment of vision loss |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| RS57840B1 (sr) | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3322443A1 (en) * | 2015-07-13 | 2018-05-23 | Yeda Research and Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| KR20200029627A (ko) * | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| KR101844596B1 (ko) * | 2014-03-18 | 2018-04-05 | 한국과학기술원 | 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물 |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| SMT201900702T1 (it) * | 2015-01-08 | 2020-01-14 | Genmab As | Agenti agonistici leganti il recettore del tnf |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2016145085A2 (en) | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| GB201506868D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| AU2016271111B2 (en) | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| MY206406A (en) * | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| WO2017063162A1 (zh) * | 2015-10-15 | 2017-04-20 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| JP7328761B2 (ja) | 2016-01-11 | 2023-08-17 | インヒブルクス インコーポレイテッド | 多価多重特異性ｏｘ４０結合融合タンパク質 |
| WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| KR102585976B1 (ko) | 2016-08-17 | 2023-10-05 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP7348072B2 (ja) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| EP3762400A4 (en) * | 2018-03-08 | 2022-03-16 | Magenta Therapeutics, Inc. | ANTI-CD252 ANTIBODIES, CONJUGATES AND METHODS OF USE |
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| ES3014697T3 (en) | 2018-07-19 | 2025-04-24 | Ichnos Sciences S A | Liquid antibody formulation |
| AU2019321490B2 (en) | 2018-08-13 | 2025-09-04 | Inhibrx Biosciences, Inc. | Ox40-binding polypeptides and uses thereof |
| EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| EP3766481A1 (en) * | 2019-07-19 | 2021-01-20 | Ichnos Sciences SA | Liquid antibody formulation |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| PE20221506A1 (es) | 2019-12-17 | 2022-10-04 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| WO2023064958A1 (en) | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| EP4507779A1 (en) | 2022-04-14 | 2025-02-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN122029196A (zh) * | 2023-10-06 | 2026-05-12 | 伊克诺斯科学公司 | 亲和力成熟的抗ox40抗体及其用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) * | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
| US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| GB0123276D0 (en) * | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0124317D0 (en) * | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| US20040009174A1 (en) | 2001-12-18 | 2004-01-15 | Arndt Gregory Martin | Method of treating asthma |
| US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| WO2004051268A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CA2528903C (en) * | 2004-12-20 | 2008-01-15 | Honda Motor Co., Ltd. | Braking device for motorcycle |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| WO2007065433A2 (en) | 2005-12-05 | 2007-06-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
| EP2010207A4 (en) | 2006-03-22 | 2009-12-02 | Imp Innovations Ltd | COMPOSITIONS AND METHODS RELATING TO THE MODULATION OF COMPONENTS OF THE IMMUNE SYSTEM |
| US20070224627A1 (en) * | 2006-03-23 | 2007-09-27 | Lawrence Horowitz | Facilitation of translocation of molecules through the gastrointestinal tract |
| KR20100014588A (ko) * | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| SI2242771T1 (sl) * | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Vezane molekule k humanemu ox40 receptorju |
| AU2010216152B2 (en) * | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| WO2011030107A1 (en) * | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) * | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| KR102119840B1 (ko) * | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
-
2010
- 2010-02-17 AU AU2010216152A patent/AU2010216152B2/en not_active Ceased
- 2010-02-17 CA CA2751477A patent/CA2751477C/en active Active
- 2010-02-17 SG SG2011057528A patent/SG173620A1/en unknown
- 2010-02-17 HU HUE10744211A patent/HUE042114T2/hu unknown
- 2010-02-17 UY UY0001032451A patent/UY32451A/es not_active Application Discontinuation
- 2010-02-17 MX MX2011008697A patent/MX2011008697A/es active IP Right Grant
- 2010-02-17 WO PCT/US2010/024377 patent/WO2010096418A2/en not_active Ceased
- 2010-02-17 CN CN201080017854.0A patent/CN102741287B/zh not_active Expired - Fee Related
- 2010-02-17 EP EP10744211.3A patent/EP2398498B1/en active Active
- 2010-02-17 SG SG10201505038TA patent/SG10201505038TA/en unknown
- 2010-02-17 PL PL10744211T patent/PL2398498T3/pl unknown
- 2010-02-17 MY MYPI2011003526A patent/MY157473A/en unknown
- 2010-02-17 LT LTEP10744211.3T patent/LT2398498T/lt unknown
- 2010-02-17 PT PT10744211T patent/PT2398498T/pt unknown
- 2010-02-17 BR BRPI1008692A patent/BRPI1008692B8/pt not_active IP Right Cessation
- 2010-02-17 DK DK10744211.3T patent/DK2398498T3/en active
- 2010-02-17 AR ARP100100457A patent/AR075504A1/es active IP Right Grant
- 2010-02-17 JP JP2011551173A patent/JP5782385B2/ja not_active Expired - Fee Related
- 2010-02-17 EA EA201171060A patent/EA037792B1/ru unknown
- 2010-02-17 US US12/706,993 patent/US8614295B2/en not_active Expired - Fee Related
- 2010-02-17 SI SI201031802T patent/SI2398498T1/sl unknown
- 2010-02-17 HR HRP20181932TT patent/HRP20181932T1/hr unknown
- 2010-02-17 NZ NZ594315A patent/NZ594315A/xx not_active IP Right Cessation
- 2010-02-17 MA MA34167A patent/MA33122B1/fr unknown
- 2010-02-17 SG SG2014014708A patent/SG2014014708A/en unknown
- 2010-02-17 ES ES10744211T patent/ES2699716T3/es active Active
- 2010-02-17 KR KR1020117021615A patent/KR101761929B1/ko not_active Expired - Fee Related
- 2010-02-17 PE PE2011001494A patent/PE20120211A1/es not_active Application Discontinuation
- 2010-02-17 UA UAA201111078A patent/UA107341C2/uk unknown
- 2010-02-22 TW TW099104929A patent/TWI476281B/zh not_active IP Right Cessation
-
2011
- 2011-07-25 IL IL214282A patent/IL214282A/en active IP Right Grant
- 2011-07-26 ZA ZA2011/05500A patent/ZA201105500B/en unknown
- 2011-08-02 TN TN2011000374A patent/TN2011000374A1/fr unknown
- 2011-08-08 CO CO11100099A patent/CO6410312A2/es active IP Right Grant
- 2011-08-16 CL CL2011001994A patent/CL2011001994A1/es unknown
-
2013
- 2013-08-22 US US13/973,189 patent/US9428570B2/en active Active
-
2015
- 2015-03-26 JP JP2015063849A patent/JP2015171362A/ja active Pending
-
2016
- 2016-08-19 US US15/242,135 patent/US10017575B2/en not_active Expired - Fee Related
-
2018
- 2018-12-04 CY CY20181101288T patent/CY1121431T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220267476A1 (en) | Multispecific antibody constructs | |
| RU2018146158A (ru) | Антитела | |
| JP2009225799A5 (enExample) | ||
| JP2019151634A5 (enExample) | ||
| JP2018526981A5 (enExample) | ||
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| JP2011527902A5 (enExample) | ||
| JP2011504501A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2017533694A5 (enExample) | ||
| JP2013545455A5 (enExample) | ||
| JP2012501669A5 (enExample) | ||
| JP2015519375A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| CN107148281A (zh) | 结合cxcr5的抗原结合蛋白 | |
| JP2011527899A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| JP2014529610A5 (enExample) | ||
| JP2019505565A5 (enExample) | ||
| JP2018508218A5 (enExample) | ||
| JP2016006052A5 (enExample) | ||
| CN114846026B (zh) | 对人il-13和il-17具有结合特异性的多特异性抗体 | |
| CN114829398B (zh) | 对人il-13具有结合特异性的抗体 | |
| RU2018126315A (ru) | Молекулы антител, которые связываются с tnf-альфа |